TSX Venture: NID
CAMPBELLVILLE, ON, June 28 /CNW/ - NIR Diagnostics Inc. (TSX Venture:
NID), a leading-edge developer of near-infrared medical instruments, today
announced that at its Annual and Special Meeting of Shareholders held on
June 28, 2007, shareholders approved amendments to the Company's 2003 Stock
Option Plan (the "Plan"). The amendments included an increase in the number of
shares reserved for issuance under the Plan from 4,750,000 to 6,750,000. The
amendments are subject to regulatory approval.
Also today, the Company announced grants of stock options to five
independent directors of the Company. At a meeting on June 28, 2007, the Board
of Directors of NIR Diagnostics Inc. granted such independent directors an
aggregate of 100,000 stock options at an exercise price of $0.16 per option.
In accordance with the Plan, the options have a term of 5 years and vest over
an eighteen month period.
About NIR Diagnostics
NIR Diagnostics is a leader in the development of near-infrared,
spectroscopic medical diagnostics. The Company has an extensive portfolio of
optical, electronic and algorithm related patents in the field of in-vitro and
in-vivo blood analysis.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this release.
For further information:
For further information: Duncan MacIntyre, President, CEO and Executive
Vice Chairman, NIR Diagnostics Inc., (905) 854-5727, (905) 854-5729 Fax,
E-mail: email@example.com, Internet: www.nirdiagnostics.com; Ross
Marshall, Investor Relations, (416) 815-0700 ext. 238, (416) 815-0080 Fax,
E-mail: firstname.lastname@example.org, Internet: www.equicomgroup.com